
FDA Accepts NDA for Investigational HIV Regimen, Doravirine/Islatravir
The FDA has accepted for review Merck’s NDA for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV that is virologically suppressed on antiretroviral therapy (ART), according to a news …